Don't miss a thing - Add info@realpennies.com to your e-mail address book!
RealPennies.com: Featured Company Profile | ||||
Now let's get down to business! We at RealPennies have been hard at work trying to find our next featured company. With all of the new advances going on in medicine today, I truly feel this one is a real breakthrough. Which is why I'm really excited to introduce this company to you! I feel this company will see major development in 2008! I recently came across an article stating that more than 10 million people are diagnosed with cancer each year. And, according to the World Health Organization, this number is expected to reach 15 million in 12 years. I'm sure there is no need for me to go into any further detail of how serious this disease is. Unfortunately, many of us know first hand the devastating effects of cancer. BioCurex (trading under the ticker symbol BOCX), is a Biotechnology company, with a core technology that identifies a cancer marker known as RECAF. This 'marker' is found only on malignant cells in a variety of cancers, but absent in normal and most benign cells. Its results have proven successful detection of cancer cells in blood or tissue samples. And according to BioCurex.com, these detection levels are significantly above any present method. That's pretty major when considering that the chance of a cure increases substantially if the disease is detected early. RECAF (among its other uses) makes this possible. In addition to prevention, RECAF makes it possible to specifically target and treat the cancer without damaging healthy cells. This is made possible for every type of cancer tissue studied. I believe BioCurex's RECAF technology has the potential to revolutionize cancer detection and treatment. As BioCurex being only the second diagnostic manufacturer with access to RECAF, I think BOCX will encounter phenomenal growth in 2008 and beyond. I am thrilled to be one of the first to introduce this to you all! READ THE FULL PROFILE:
-- Disclaimer: |
|
|
No comments:
Post a Comment